Back to Agenda
Session 4: Evolving the Clinical Trial Landscape Using Real-World Data
Session Chair(s)
Brad Jordan, PHD
Associate Vice President, Regulatory Policy and Strategy, Eli Lilly and Company, United States
Mark Stewart, PHD
Vice President, Science Policy, Friends of Cancer Research, United States
The past several years has seen a necessary evolution in how clinical research is performed. At the forefront of this is the utilization of real-world data to inform clinical trial design, develop diversity plans, and facilitate the conduct of clinical trials at the point of care. This session will examine the present and future contribution of RWD and highlight important efforts and case study examples aimed at using RWD to contribute to the transformation of clinical research and clinical trial design for improved regulatory and health care decision-making.
Learning Objective : At the conclusion of this session, participants will:- Recognize how real-world data can be used to assist in study design and as a data source to facilitate clinical research
- Apply lessons learned and strategies from recent efforts and case studies to support clinical research and trial designs
- Understand experiences to date and identify practical and technological considerations to further implement real-world clinical research
Speaker(s)
Raymond Harvey, MPH
Senior Director, Data Science, Johnson & Johnson Innovative Medicine, United States
Real-World Data Applications With Clinical Trials
Kraig Kinchen, MD, MS
Associate Vice President, Value, Evidence, and Outcomes, Diabetes Business Unit, Eli Lilly and Company, United States
What Role Should Point-Of-Care Trials Play In Leveraging RWD?
Rachele Hendricks-Sturrup, MA
Research Director, Real-World Evidence, Duke-Margolis Institute For Health Policy (DMI), United States
An Update On The State Of Real-World Evidence Policy
Have an account?